MedPath

CENTOCOR, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
1.2K
Market Cap
-
Website
http://www.centocor.com

A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-03-05
Last Posted Date
2014-05-28
Lead Sponsor
Centocor, Inc.
Target Recruit Count
24
Registration Number
NCT01081704

A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis

Phase 3
Completed
Conditions
Psoriasis
Interventions
Drug: placebo
Drug: ustekinumab
First Posted Date
2009-11-06
Last Posted Date
2013-11-11
Lead Sponsor
Centocor, Inc.
Target Recruit Count
322
Registration Number
NCT01008995

An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

Phase 3
Completed
Conditions
Arthritis, Rheumatoid
Interventions
First Posted Date
2009-09-09
Last Posted Date
2013-12-25
Lead Sponsor
Centocor, Inc.
Target Recruit Count
592
Registration Number
NCT00973479

A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

Phase 2
Completed
Conditions
Sarcoidosis
Interventions
First Posted Date
2009-08-10
Last Posted Date
2014-07-17
Lead Sponsor
Centocor, Inc.
Target Recruit Count
173
Registration Number
NCT00955279

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Phase 1
Completed
Conditions
Psoriasis
First Posted Date
2009-06-22
Last Posted Date
2017-09-05
Lead Sponsor
Centocor, Inc.
Target Recruit Count
71
Registration Number
NCT00925574

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: CNTO 3649 SC (Healthy participants)
Drug: CNTO 3649 IV (Healthy participants)
Drug: CNTO 3649 SC (Diabetic patients)
Drug: Placebo
First Posted Date
2009-04-16
Last Posted Date
2013-12-16
Lead Sponsor
Centocor, Inc.
Target Recruit Count
133
Registration Number
NCT00882726

A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers

Phase 1
Completed
Conditions
Healthy
First Posted Date
2009-02-16
Last Posted Date
2010-04-27
Lead Sponsor
Centocor, Inc.
Target Recruit Count
62
Registration Number
NCT00844909

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Phase 1
Completed
Conditions
Head and Neck Neoplasms
Lung Neoplasms
Ovarian Neoplasms
Pancreatic Neoplasms
Colorectal Neoplasms
Interventions
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
First Posted Date
2009-02-11
Last Posted Date
2014-05-14
Lead Sponsor
Centocor, Inc.
Target Recruit Count
84
Registration Number
NCT00841191

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2
Completed
Conditions
Pulmonary Fibrosis
Interventions
Drug: Placebo
Drug: CNTO 888 1 mg/kg
Drug: CNTO 888 5 mg/kg
Drug: CNTO 888 15 mg/kg
First Posted Date
2008-11-06
Last Posted Date
2015-12-28
Lead Sponsor
Centocor, Inc.
Target Recruit Count
126
Registration Number
NCT00786201
© Copyright 2025. All Rights Reserved by MedPath